Hypersensitivity reactions to blood components: Document issued by the allergy committee of the French medicines and healthcare products regulatory agency

Journal of Investigational Allergology and Clinical Immunology

Volumn 21, Issue 3, 2011, Pages 171-178

  Mertes, P M ^a   Bazin, A ^b   Alla, F ^a   Bienvenu, J ^c   Caldani, C ^d   Lamy, B ^e   Laroche, D ^b   Leconte des Floris, M F ^f   Py, J Y ^f   Rebibo, D ^f   Willaert, B ^d   Demoly, P ^g  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU   (France)

^c UNIVERSITÉ DE LYON   (France)

^d AFSSAPS   (France)

^e Agence Régionale de Santé de Bourgogne Franche Comté   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

^g HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Anaphylaxis; Blood component; Diagnosis procedure; Hypersensitivity

Indexed keywords

IMMUNOGLOBULIN E;

ADVERSE OUTCOME; ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BLOOD COMPONENT; BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; CAUSAL ATTRIBUTION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FRANCE; GASTROINTESTINAL SYMPTOM; GOVERNMENT REGULATION; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY REACTION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; QUALITY CONTROL; RECIPIENT; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION;

BLOOD COMPONENT TRANSFUSION; FRANCE; HEALTH POLICY; HUMANS; HYPERSENSITIVITY; PRACTICE GUIDELINES AS TOPIC;

EID: 79955454064     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. AFSSAPS. Hémovigilance. Fiche technique allergie. Updated 2009. Available from: www.afssaps.fr.
2. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832-6.
3. Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008;8:310-5.
4. Wibaut B, Mannessier L, Horbez C, Coupez B, Courbon B, Mizon P, Goudemand J. Anaphylactic reactions associated with anti-Chido Antibody following platelet transfusions. Vox Sang. 1995;69:150-1.
5. Lambin P, Le Pennec PY, Hauptmann G, Desaint O, Habibi B, Salmon C. Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodgers specifi city. Vox Sang. 1984;47:242-9.
6. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995;125:348-55.
7. Kadar JG, Schuster J, Hunzelmann N. IgE-mediated anaphylactic reaction to purifi ed and recombinant factor VIII in a patient with severe haemophilia A. Haemophilia. 2007;13:104-5.
8. Vassallo RR. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgAdefi cient products. Immunohematology. 2004;20:226-33.
9. Gilstad CW. Anaphylactic transfusion reactions. Curr Opin Hematol. 2003;10:419-23.
10. Salkie ML, Hannon JL. Anti-plasticizer specifi c IgE is present in the serum of transfused patients. Clin Invest Med. 1995;18:419-23.
11. Dolovich J, Sagona M, Pearson F, Buccholz D, Hiner E, Marshall C. Sensitization of repeat plasmapheresis donors to ethylene oxide gas. Transfusion. 1987;27:90-3.
12. Vermylen J, Janssens S, Ceuppens J, Vermylen C. Transfusion reactions in haemophiliac caused by sensitisation to ethylene oxide. Lancet.1988;1:594.
13. Johansson SG, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L, Söderström L, Stiller V, Oman H. Passive IgEsensitization by blood transfusion. Allergy. 2005;60:1192-9.
14. Routledge RC, De Kretser DM, Wadsworth LD. Severe anaphylaxis due to passive sensitisation by donor blood. Br Med J. 1976;1:434.
15. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;1:466-8.
16. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the defi nition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med.2006;47:373-80.
17. Mertes PM, Laxenaire MC, Lienhart A, Aberer W, Ring J, Pichler WJ, Demoly P; Working Group for the SFAR; ENDA; EAACI Interest Group on Drug Hypersensitivity. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol. 2005;15:91-101.